CSIMarket
 


Fibrogen Inc   (FGEN)
Other Ticker:  
 
 

FGEN's Net Income Growth by Quarter and Year

Fibrogen Inc 's Net Income results by quarter and year




FGEN Net Income (in millions $) FY 2023 FY 2022 FY 2021 FY 2020
IV Quarter December - -66.18 -134.08 33.00
III Quarter September -63.62 -91.65 49.80 -85.31
II Quarter June -87.68 -72.62 -133.99 -78.35
I Quarter March -76.71 -63.21 -71.76 -98.12
FY   -228.01 -293.66 -290.03 -228.78



FGEN Net Income third quarter 2023 Y/Y Growth Comment
Fibrogen Inc in the third quarter 2023 recorded net loss of $ -63.62 millions.

According to the results reported in the third quarter 2023, Fibrogen Inc achieved the best Net Income growth in Major Pharmaceutical Preparations industry. While Fibrogen Inc ' s Net Income no change of % ranks overall at the positon no. in the third quarter 2023.




FGEN Net Income ( Y/Y Growth %) 2023
2022 2021 2020
IV Quarter December - - - -
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - - - -
FY   - - - -

Financial Statements
Fibrogen Inc 's third quarter 2023 Net Income $ -63.62 millions FGEN's Income Statement
Fibrogen Inc 's third quarter 2022 Net Income $ -91.65 millions Quarterly FGEN's Income Statement
New: More FGEN's historic Net Income Growth >>


FGEN Net Income (Quarter on Quarter Growth %)

2023
2022 2021 2020
IV Quarter December - - - -
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - - - -
FY (Year on Year)   - - - -




Net Income third quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Net Income Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 
Net Income third quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Net Income Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 

Net Income by Quarter for the Fiscal Years 2020, 2021, 2022, 2023

Fibrogen Inc 's Q/Q Net Income Growth


Net Income Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


FGEN's III. Quarter Q/Q Net Income Comment
Despite the fact, that Fibrogen Inc in the III. Quarter 2023 admitted net loss of $ -63.62 millions, management said, that this are improvement in contrast to the -87.68 millions in the second quarter.

Within Major Pharmaceutical Preparations industry Fibrogen Inc achieved highest sequential Net Income growth. While Fibrogen Inc 's Net Income growth quarter on quarter, overall rank is .


Net Income Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Net Income Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Net Income Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


FGEN's III. Quarter Q/Q Net Income Comment
Although Fibrogen Inc in the III. Quarter 2023 showed net loss of $ -63.62 millions, some analyst point out, that those numbers show recovery compare to the -87.68 millions in the second quarter.

Within Major Pharmaceutical Preparations industry Fibrogen Inc achieved highest sequential Net Income growth. While Fibrogen Inc 's Net Income growth quarter on quarter, overall rank is .


Fibrogen Inc 's 12 Months Net Income Growth Year on Year


Net Income TTM Growth

12 Months Ending
(Sep 30 2023)
12 Months Ending
(Jun 30 2023)
12 Months Ending
(Mar 31 2023)
12 Months Ending
(Dec 31 2022)
12 Months Ending
(Sep 30 2022)
Cumulative Net Income 12 Months Ending $ -294.18 $ -322.21 $ -307.15 $ -293.65 $ -361.56
Y / Y Net Income Growth (TTM) - - - - -
Year on Year Net Income Growth Overall Ranking # # # # #
Seqeuential Net Income Change (TTM) - - - - -
Seq. Net Income Growth (TTM) Overall Ranking # # # # #




Cumulative Net Income growth Comment


Fibrogen Inc achieved highest trailing twelve month year on year Net Income growth. While overall Net Income growth ranking, remained unchanged compare to the previous quarter at no. .

Net Income TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 

Net Income TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Net Income TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Net Income TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #
Cumulative Net Income growth Comment


Fibrogen Inc achieved highest trailing twelve month year on year Net Income growth. While overall Net Income growth ranking, remained unchanged compare to the previous quarter at no. .

Net Income TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 


Net Income TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Net Income TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Net Income TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #




Other Net Income Growth
Major Pharmaceutical Preparations Industry Net Income Growth Trends and Statistics
Healthcare Sector Net Income Growth Statistics
Net Income Growth Trends for overall market
FGEN's Net Income Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Net Income Growth
Lowest Ranking Net Income Growth
Net Income Growth for FGEN's Competitors
Net Income Growth for Fibrogen Inc 's Suppliers
Net Income Growth for FGEN's Customers

You may also want to know
FGEN's Annual Growth Rates FGEN's Profitability Ratios FGEN's Asset Turnover Ratio FGEN's Dividend Growth
FGEN's Roe FGEN's Valuation Ratios FGEN's Financial Strength Ratios FGEN's Dividend Payout Ratio
FGEN's Roa FGEN's Inventory Turnover Ratio FGEN's Growth Rates FGEN's Dividend Comparisons



Companies with similar Net Income no change for the quarter ending Sep 30 2023 within Healthcare SectorY/Y Change %Net Income for the quarter ending Sep 30 2023
Shockwave Medical Inc -0.05%$ -0.049 millions
Xeris Biopharma Holdings Inc -0.29%$ -0.295 millions
Tenet Healthcare Corp-0.75%$ -0.746 millions
U S Physical Therapy Inc-4.67%$ -4.672 millions
Universal Health Services Inc -4.98%$ -4.979 millions
National Research Corporation-5.09%$ -5.086 millions
Hca Healthcare Inc -5.13%$ -5.134 millions
Viatris Inc -6.41%$ -6.407 millions
Pacific Health Care Organization Inc -6.71%$ -6.710 millions
Mettler Toledo International Inc-8.60%$ -8.598 millions
Corcept Therapeutics Inc-9.78%$ -9.777 millions
Charles River Laboratories International inc -9.83%$ -9.826 millions
Third Harmonic Bio Inc -10.51%$ -10.506 millions
The Pennant Group Inc -10.65%$ -10.653 millions
Henry Schein Inc -11.73%$ -11.728 millions
Quest Diagnostics Inc-14.13%$ -14.130 millions
Stryker Corp-15.20%$ -15.196 millions
Zimmer Biomet Holdings Inc -16.12%$ -16.117 millions
Amgen Inc -19.27%$ -19.272 millions
Entera Bio Ltd -22.43%$ -22.432 millions
Regeneron Pharmaceuticals Inc -23.40%$ -23.402 millions
Zynex inc -26.25%$ -26.247 millions
Evofem Biosciences Inc -26.26%$ -26.256 millions
Pediatrix Medical Group Inc -30.39%$ -30.386 millions
Tenax Therapeutics Inc -32.39%$ -32.386 millions
Avantor Inc -35.09%$ -35.090 millions
Ufp Technologies Inc -40.15%$ -40.154 millions
Bio techne Corp-43.17%$ -43.173 millions
Royalty Pharma Plc-44.61%$ -44.615 millions
American Shared Hospital Services-46.43%$ -46.429 millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com